Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

RNA-targeted therapy

Therapeutic area intelligence for RNA-targeted therapy with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 3

Companies

AstraZeneca →

Ionis Pharmaceuticals →

IONIS PHARMS INC. →

Assets

Recent signals(5)

RegulatoryJuly 26, 2026

AstraZeneca's EPLONTERSEN SODIUM Autoinjector Receives AP Status from FDA

The FDA has granted an Approval Pending (AP) status for AstraZeneca's autoinjector application for EPLONTERSEN SODIUM.

July 13, 2026

Ionis Pharmaceuticals Evaluates Sapablursen in Polycythemia Vera Patients

Ionis Pharmaceuticals is conducting a study to assess the efficacy of sapablursen in reducing phlebotomy frequency and improving quality of life in polycythemia vera patients.

RegulatoryJuly 3, 2026

FDA Accepts Supplemental Application for WAINUA Autoinjector by AstraZeneca

The FDA has accepted a supplemental application for the WAINUA autoinjector containing EPLONTERSEN SODIUM.

RegulatoryJune 30, 2026

FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector

The FDA has accepted a supplemental application for the TRYNGOLZA autoinjector, indicating progress in its regulatory pathway.

RegulatoryJune 27, 2026

FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission

The FDA has granted priority review for the supplemental application of TRYNGOLZA (olezarsen sodium) autoinjector by Ionis Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.